General
Preferred name
PACRITINIB
Synonyms
ONX-0803, SB-1518, SB1518 ()
SB1518 ()
Pacritinib (SB1518) ()
SB-1518 ()
ONX-0803 ()
P&D ID
PD010466
CAS
937272-79-2
Tags
obsolete probe
natural product
drug
available
Approved by
FDA
First approval
2022
Drug Status
investigational
approved
Drug indication
Myelofibrosis
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Pacritinib is an orally bioavailable and somewhat selective inhibitor of Janus kinase 2 (JAK2) and the JAK2 gain-of-function mutant JAK2V617F . At clinically relevant concentrations, pacritinib does not inhibit JAK1. It also has some inhibitory activity against FMS-like tyrosine kinase 3 (FLT3). (GtoPdb)
Cell lines
13
Organisms
0
Compound Sets
17
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Clinical kinase drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Obsolete Compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
External IDs
27
Properties
(calculated by RDKit )
Molecular Weight
472.25
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
5
Aromatic Ring Count
2
cLogP
4.47
TPSA
67.68
Fraction CSP3
0.36
Chiral centers
0.0
Largest ring
18.0
QED
0.67
Structural alerts
1
historic compounds (Chemical Probes.org)
Obsolete
Custom attributes
(extracted from source data)
Targets
JAK2,FLT3
Pathway
Angiogenesis
Tyrosine Kinase/Adaptors
Chromatin/Epigenetic
JAK/STAT Signaling
Stem Cells
Epigenetics
Protein Tyrosine Kinase/RTK
Stem Cell/Wnt
Target
FLT3
FLT3 (D835Y)
JAK2
JAK2 (V617F)
TYK2
JAK3
FLT3, JAK1, JAK2, JAK3
JAK
FLT3,JAK
MOA
FLT3 inhibitor, JAK inhibitor
Source data